首页> 外文期刊>The Surgeon >Synchronous liver resection and cryotherapy for colorectal metastases: Survival analysis
【24h】

Synchronous liver resection and cryotherapy for colorectal metastases: Survival analysis

机译:同步肝切除和冷冻治疗结直肠转移的生存分析

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: The value of synchronous liver resection and cryotherapy ablation remains controversial for colorectal metastases where complete resection is not possible by conventional liver surgery alone. Objective: To review the long-term survival of patients treated using this approach at our institution. Methods: A review was undertaken of data held in the prospectively collected liver surgery database of all patients who underwent synchronous liver resection and cryotherapy. Survival analysis was performed and data recorded on the total number of metastases at initial surgery and the number of lesions treated by cryoablation. Results: Ninety-three patients with colorectal metastases underwent synchronous liver resection and cryotherapy. Data were available on 86 patients with a median follow-up of 18 months (range 1-83). The median number of metastases at initial surgery was four (range 2-11) and the number of lesions treated by cryotherapy ablation was two (range 1-8). Eighty-four per cent had a hepatic artery catheter inserted at surgery and at least one cycle of post-operative hepatic artery chemotherapy. One-, three- and five-year survival was 85%, 43% and 19% respectively, with a median survival of 33 months (95% confidence interval 19.9-42.1). Site of recurrence was recorded and presented. Conclusions: Patients with liver metastases that are not amenable to resection alone can achieve worthwhile median survival with synchronous liver resection and cryotherapy ablation
机译:简介:对于仅通过常规肝手术无法完全切除的结直肠转移,同步肝切除和冷冻疗法消融的价值仍存在争议。目的:回顾在我们机构中使用这种方法治疗的患者的长期生存。方法:对前瞻性收集的肝脏手术数据库中所有同步同步肝切除和冷冻治疗患者的数据进行了回顾。进行生存分析,并记录有关初次手术时转移的总数和通过冷冻消融治疗的病变数的数据。结果:93例大肠转移患者接受了同步肝切除和冷冻治疗。现有86位患者的数据,中位随访18个月(范围1-83)。初次手术转移的中位数为四个(范围2-11),通过冷冻疗法消融治疗的病灶数目为两个(范围1-8)。 84%的人在手术时插入了肝动脉导管,并在术后至少一个周期进行了肝动脉化疗。一年,三年和五年生存率分别为85%,43%和19%,中位生存期为33个月(95%置信区间19.9-42.1)。记录并显示复发部位。结论:不适合单独切除的肝转移患者可以通过同步肝切除和冷冻疗法消融获得有价值的中位生存期

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号